Roche Ends Deal with Ligand

11/24/10

San Diego’s Ligand Pharmaceuticals (NASDAQ: LGNDD) said today that Roche has terminated their collaboration and licensing agreement to develop a treatment for hepatitis C, according to a regulatory filing. Ligand and the Swiss pharmaceutical giant signed the drug development deal two years ago, and Roche made a $6.5 million milestone payment to Roche in April.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.